SPARC has encouraging revenue growth and potential

SPARC Sun Pharma Advanced Research Company (SPARC) is a pharmaceutical R&D company focused on developing innovative medicines and speciality treatments. In its latest Q2 FY27 results, the company reported revenue from operations of approximately ₹30.03 crore, up 282% year-on-year, but still reported a consolidated net loss of ₹24.39 crore, indicating that profitability remains a challenge. For H1 FY27, revenue increased approximately 300% year-on-year to ₹69.95 crore. An important development was the company's sale of a USFDA Priority Review Voucher (PRV) for USD 195 million in April 2026, following its grant for Sezaby. However, this generated exceptional income and should not be considered recurring operating revenue. Going forward, investors should monitor its drug-development pipeline, regulatory approvals, revenue growth and reduction in R&D-related losses. SPARC has encouraging revenue growth and potential from its research pipeline, but consistent profitability is yet to be established. A strong technical trend above all four EMAs would indicate improving market sentiment, while fundamental improvement needs to be confirmed through sustainable earnings growth.